The NeurologyLive® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical focus page is a concentrated place for the latest information on the care and management of patients with CIDP. This page includes podcasts, videos and expert interviews, and news about the latest study and clinical trial findings, FDA actions, and clinical guideline updates.
June 24th 2025
Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.